![]() |
|
|
Vol. 302, Issue 3, 1246-1252, September 2002
Department of Molecular and Cellular Pharmacology, University of
Miami School of Medicine, Miami, Florida (M.A., M.J.P., F.N.M, C.W.L.);
and Chemistry and Life Sciences, Research Triangle Institute, Research
Triangle Park, North Carolina (F.I.C.)
2'-Pyridine ring substituted analogs of epibatidine were assessed for
equilibrium binding affinity, functional potency, and efficacy at rat
neuronal nicotinic receptors expressed in Xenopus oocytes. Binding affinities were determined in membrane homogenates from oocytes expressing
2
2,
2
4,
3
2,
3
4,
4
2, or
4
4. Efficacy (relative to acetylcholine) and
potency were measured electrophysiologically with oocytes expressing
3
4,
4
2, and
4
4. Hydroxy, dimethylamino, and
trifluoromethanesulfonate analogs had affinities too low for accurate
measurement. The bromo analog had affinities 4- to 55-fold greater at
2 than at
4-containing receptors, modestly greater efficacy at
4
4 than at
4
2, and 5- to 10-fold greater potency at a4
4
than at
3
4 or
4
2. The fluoro analog displayed affinities
52- to 875-fold greater at
2- than at
4-containing receptors,
efficacy at
4
4 receptors 3-fold greater than at
4
2 and
3
4, and was equipotent at all receptors tested. The norchloro
analog showed affinities 114- to 3500-fold greater at
2- than at
4-containing receptors, 2-fold greater efficacy at
4
2 and
4
4 than at
3
4, and 4- to 5-fold greater potency at
4
4
and
3
4 than at
4
2. The amino analog displayed affinities
10- to 115-fold greater at
2- than at
4-containing receptors,
3-fold greater efficacy at
3
4 than at
4
2, and 2- to 4-fold
greater potency at
3
4 and
4
4 than at
4
2. Although these compounds displayed a variety of differences in affinity, efficacy, and potency, with one exception (binding affinity and functional potency at
4
4 receptors) there were no significant correlations among these properties.
This article has been cited by other articles:
![]() |
K. B. Mihalak, F. I. Carroll, and C. W. Luetje Varenicline Is a Partial Agonist at {alpha}4beta2 and a Full Agonist at {alpha}7 Neuronal Nicotinic Receptors Mol. Pharmacol., September 1, 2006; 70(3): 801 - 805. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Akk, L. S Milescu, and M. Heckmann Activation of heteroliganded mouse muscle nicotinic receptors J. Physiol., April 15, 2005; 564(2): 359 - 376. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Jensen, I. Mikkelsen, B. Frolund, H. Brauner-Osborne, E. Falch, and P. Krogsgaard-Larsen Carbamoylcholine Homologs: Novel and Potent Agonists at Neuronal Nicotinic Acetylcholine Receptors Mol. Pharmacol., October 1, 2003; 64(4): 865 - 875. [Abstract] [Full Text] [PDF] |
||||